EP 814 Risks & Benefits of Daily Aspirin Therapy

Chronic inflammation is a grim predictor of cardiovascular events like heart attack and stroke.

As an anti-inflammatory, daily aspirin therapy can be a lifesaving option.

But, it's not for everyone.

Charles H. Hennekens, MD, DrPH, first Sir Richard Doll Professor & Senior Academic Advisor to the Dean, Charles E. Schmidt College of Medicine at Florida Atlantic University, believes aspirin therapy should be an individual judgement between you and your physician; one that ways the benefits and the risks.

Dr. Hennekens is also the author of a new study that revealed a special toothpaste (called Plaque HD) significantly reduced dental plaque in the mouth and inflammation throughout the entire body.

During this podcast, Dr. Hennekens talks about the study and why it's important, especially for people with heart disease or heart risks.

**Make sure to tune into the coming Episode 816 (released Tuesday, November 29, 2016) to hear more about Plaque HD.
EP 814 Risks & Benefits of Daily Aspirin Therapy
Featuring:
Charles H. Hennekens, MD, DrPH
Charles-HennekensCharles H. Hennekens, MD, DrPH, is the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton, Florida. Dr. Charles Hennekens is one of the leading medical researchers in the world and was recently honored as "Doctor of the Decade" by Science Watch for being the third most widely cited medical researcher in the world from 1995 to 2005. In addition, five of the top 20 were his former fellows and/or trainees. In 2012, ScienceHeroes.com ranked Dr. Charles Hennekens No. 81 in the history of the world for having saved more than one million human lives.

Over the course of his medical career. Professor Charles Hennekens was the first John Snow Professor of Medicine as well as the first Eugene Braunwald Professor of Medicine at Harvard Medical School. He also was the first Chief of Preventive Medicine at Brigham and Women's Hospital. Dr. Charles Hennekens' medical research has elucidated numerous causal and preventive factors in cardiovascular disease and cancer. He is particularly recognized for being the first to discover that aspirin prevents a first heart attack and reduces the death rate when given during a heart attack, as well as to a wide range of survivors of prior events.

Continuing to engage in medical research projects, he serves as a Visiting Fellow at the University of Oxford, Green College, where he collaborates with the Clinical Trial Service and Epidemiological Studies Unit (CTSU). He is a member of many editorial boards of peer-reviewed medical publications, including the Journal of Health Disparity and the Journal of Cardiovascular Pharmacology and Therapeutics.